87 related articles for article (PubMed ID: 20003427)
1. No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study.
Stolk P; Heemstra HE; Leufkens HG; Bloechl-Daum B; Heerdink ER
Orphanet J Rare Dis; 2009 Dec; 4():27. PubMed ID: 20003427
[TBL] [Abstract][Full Text] [Related]
2. Trends in orphan medicinal products approvals in the European Union between 2010-2022.
Bouwman L; Sepodes B; Leufkens H; Torre C
Orphanet J Rare Dis; 2024 Feb; 19(1):91. PubMed ID: 38413985
[TBL] [Abstract][Full Text] [Related]
3. The legal imperative for treating rare disorders.
Hyry HI; Roos JC; Manuel J; Cox TM
Orphanet J Rare Dis; 2013 Sep; 8():135. PubMed ID: 24010951
[TBL] [Abstract][Full Text] [Related]
4. Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer.
Vassal G; Kearns P; Blanc P; Scobie N; Heenen D; Pearson A
Eur J Cancer; 2017 Oct; 84():149-158. PubMed ID: 28818704
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness, safety and costs of orphan drugs: an evidence-based review.
Onakpoya IJ; Spencer EA; Thompson MJ; Heneghan CJ
BMJ Open; 2015 Jun; 5(6):e007199. PubMed ID: 26109112
[TBL] [Abstract][Full Text] [Related]
6. The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products.
Palomo GM; Pose-Boirazian T; Naumann-Winter F; Costa E; Duarte DM; Kalland ME; Malikova E; Matusevicius D; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
Mol Ther; 2023 Dec; 31(12):3414-3423. PubMed ID: 37794679
[TBL] [Abstract][Full Text] [Related]
7. Emergent treatments for β-thalassemia and orphan drug legislations.
Costa E; Cappellini MD; Rivella S; Chilin A; Alessi E; Riccaboni M; Leufkens HGM; Luzzatto L
Drug Discov Today; 2022 Nov; 27(11):103342. PubMed ID: 36058507
[TBL] [Abstract][Full Text] [Related]
8. Trends from two decades of orphan designations in paediatric rare neuromuscular diseases.
Duarte DM; da Silva Lima MB; Sepodes B
J Neurol Sci; 2024 May; 460():122989. PubMed ID: 38581740
[TBL] [Abstract][Full Text] [Related]
9. Uptake of orphan drugs in the WHO essential medicines lists.
Costa E; Moja L; Wirtz VJ; van den Ham HA; Huttner B; Magrini N; Leufkens HG
Bull World Health Organ; 2024 Jan; 102(1):22-31. PubMed ID: 38164340
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical policy and innovation for rare diseases: A narrative review.
Alonso Ruiz A; Large K; Moon S; Vieira M
F1000Res; 2023; 12():211. PubMed ID: 38778810
[TBL] [Abstract][Full Text] [Related]
11. Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation.
Tu SS; Nagar S; Kesselheim AS; Lu Z; Rome BN
JAMA; 2023 May; 329(18):1607-1608. PubMed ID: 37159041
[TBL] [Abstract][Full Text] [Related]
12. Use of biomarkers in the context of orphan medicines designation in the European Union.
Tsigkos S; Llinares J; Mariz S; Aarum S; Fregonese L; Dembowska-Baginska B; Elbers R; Evers P; Foltanova T; Lhoir A; Corrêa-Nunes A; O'Connor D; Voordouw A; Westermark K; Sepodes B
Orphanet J Rare Dis; 2014 Jan; 9():13. PubMed ID: 24461084
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study.
Lexchin J
J Gen Intern Med; 2024 May; 39(7):1276-1279. PubMed ID: 38326584
[No Abstract] [Full Text] [Related]
14. Drug reimbursement: indicators of inappropriate resource allocation.
Bégaud B; Bergman U; Eichler HG; Leufkens HG; Meier PJ
Br J Clin Pharmacol; 2002 Nov; 54(5):528-34. PubMed ID: 12445033
[TBL] [Abstract][Full Text] [Related]
15. Does pandemic uncertainty spur public health expenditures? Evidence from European Union economies.
Chang W; Zhou X; Nazar R; Ali S
Nurs Health Sci; 2023 Sep; 25(3):434-444. PubMed ID: 37565598
[TBL] [Abstract][Full Text] [Related]
16. Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales.
Pijeira Perez Y; Wood E; Hughes DA
Orphanet J Rare Dis; 2023 Nov; 18(1):342. PubMed ID: 37915031
[TBL] [Abstract][Full Text] [Related]
17. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.
Kostadinov K; Popova-Sotirova I; Marinova Y; Musurlieva N; Iskrov G; Stefanov R
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672571
[TBL] [Abstract][Full Text] [Related]
18. Oncologic orphan drugs approved in the EU - do clinical trial data correspond with real-world effectiveness?
Schuller Y; Biegstraaten M; Hollak CEM; Klümpen HJ; Gispen-de Wied CC; Stoyanova-Beninska V
Orphanet J Rare Dis; 2018 Nov; 13(1):214. PubMed ID: 30486835
[TBL] [Abstract][Full Text] [Related]
19. The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report.
Pasmooij AMG; Mol PGM; Bot JC; Leufkens HGM
Clin Pharmacol Ther; 2024 Jul; 116(1):64-71. PubMed ID: 38679943
[TBL] [Abstract][Full Text] [Related]
20. Current situation and evolution of the availability of drugs in the paediatric population in Spain.
Paradas-Palomo JD; Yunquera-Romero L; Gallego-Fernández C
Farm Hosp; 2024; 48(3):122-128. PubMed ID: 37612184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
